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In Brief
YB-1 binds DNA and RNA and has been
shown to promote epithelial-to-
mesenchymal transition and metastasis
of carcinomas. El-Naggar et al. show that
YB-1 also contributes to metastasis of
high-risk sarcomas by binding to HIF1A
mRNA and enhancing its translation.
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http://dx.doi.org/10.1016/j.ccell.2015.04.003SUMMARYMetastatic dissemination is the leading cause of death in cancer patients, which is particularly evident for
high-risk sarcomas such as Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma. Previous research
identified a crucial role for YB-1 in the epithelial-to-mesenchymal transition (EMT) andmetastasis of epithelial
malignancies. Based on clinical data and two distinct animal models, we now report that YB-1 is also a major
metastatic driver in high-risk sarcomas. Our data establish YB-1 as a critical regulator of hypoxia-inducible
factor 1a (HIF1a) expression in sarcoma cells. YB-1 enhances HIF1a protein expression by directly binding to
and activating translation of HIF1A messages. This leads to HIF1a-mediated sarcoma cell invasion and
enhanced metastatic capacity in vivo, highlighting a translationally regulated YB-1-HIF1a axis in sarcoma
metastasis.INTRODUCTION
Tumor metastasis is estimated to account for greater than 90%
of cancer-related deaths (Gupta and Massague´, 2006). Sar-
comas, malignancies of mesenchymal origin, have a particular
propensity for local invasion and metastatic spread. For
example, high-risk sarcomas, including Ewing sarcoma (EWS)
and osteosarcoma (OS), the most frequent bone sarcomas,
and rhabdomyosarcoma (RMS), the predominant childhood
soft-tissue subtype, are characterized by early metastatic
spread and poor prognosis (HaDuong et al., 2015). AlthoughSignificance
Metastatic spread is the single-most powerful predictor of poo
into molecular mechanisms underlying metastatic capacity ha
to improve therapeutic responses in these diseases. Our data
in sarcoma cells, leading to enhanced cell motility and metas
under both normoxia and hypoxia provides an additional mech
YB-1 also regulates HIF1a expression in epithelial cancers. Ou
cascade as a therapeutic strategy to prevent sarcomametasta
682 Cancer Cell 27, 682–697, May 11, 2015 ª2015 Elsevier Inc.important insights into sarcoma pathogenesis and molecular
diagnostic tools have emerged, these findings have not
impacted the prognosis for sarcoma patients with metastatic
disease. Identifying factors that contribute to sarcoma metas-
tasis and that can be targeted therapeutically thus has tremen-
dous potential to significantly impact survival outcomes for
patients having this group of diseases.
Y-box binding protein 1 (YB-1), which is encoded by YBX1, is a
conserved protein that binds both DNA and RNA to orchestrate
transcription as well as RNA processing and translation (Evdoki-
mova et al., 2006a; Kohno et al., 2003). YB-1 plays prominentr outcome in high-risk sarcomas. The lack of crucial insights
s severely hindered the development of effective strategies
establish YB-1 as a critical regulator of HIF1a expression
tatic capacity. Enhanced HIF1A mRNA translation by YB-1
anism for regulating HIF1a expression in tumors. Moreover,
r work highlights the potential for targeting the YB-1-HIF1a
sis, which could greatly impact outcomes for these diseases.
pro-oncogenic roles in malignant transformation, cell invasion,
and drug resistance in a wide variety of cancers (Evdokimova
et al., 2009; Gime´nez-Bonafe´ et al., 2004). YB-1 is a general sup-
pressor of cap-dependent translation under diverse conditions
(Evdokimova et al., 2006a; Somasekharan et al., 2012). How-
ever, some mRNAs are translationally activated by YB-1 under
specific conditions. For example, we previously demonstrated
that YB-1 blocks proliferation of breast cancer cells by repres-
sing growth-related mRNAs such as cyclins, but simultaneously
induces epithelial-to-mesenchymal transition (EMT) by directly
binding to and activating translation of mRNAs encoding Snail1
and Twist EMT factors (Evdokimova et al., 2009). This is accom-
panied by enhanced metastatic capacity, and YB-1 is upregu-
lated in invasive breast cancer and correlates with poor survival
(Evdokimova et al., 2009). Notably, recent studies highlight YB-1
itself as being translationally induced downstream of mTORC1
signaling (Thoreen et al., 2012) and as a major translationally
activated driver of mTORC1-mediated prostate cancer cell inva-
sive capacity (Hsieh et al., 2012).
Intratumoral hypoxia is a common feature of solid malig-
nancies, including sarcomas, hypoxia-inducible factor 1a
(HIF1a), along with HIF2a, is a requisite transcription factor for
cellular adaptation to hypoxia, and both proteins can strongly in-
fluence the metastatic potential of tumor cells (Semenza, 2014).
Indeed, HIF1a has well-documented roles in cancer progression
(Finger and Giaccia, 2010) and has been implicated in sarcoma
metastasis (Eisinger-Mathason et al., 2013). Under hypoxia,
HIF1a is upregulated both transcriptionally (Belaiba et al.,
2007) and through protein stabilization via functional inactivation
of the Elongin B/C-CUL2-VHL E3 ligase complex, known to
target HIF1a for proteasomal degradation (Ivan et al., 2001;
Jaakkola et al., 2001). However, the role of mRNA translation in
regulating HIF1a levels under hypoxia, particularly in tumor cells,
is poorly understood, even though increased translation is esti-
mated to account for 40%–50%of HIF1a induction under hypox-
ia (Galba´n et al., 2008; Hui et al., 2006).
Although many studies have revealed important roles for YB-1
in progression of epithelial cancers (Evdokimova et al., 2009;
Gluz et al., 2009), its contribution in sarcomas is unknown, with
only a few reports linking enhanced YB-1 expression to poor
outcome in these diseases (Fujiwara-Okada et al., 2013; Xu
et al., 2014). Because YB-1 induces an EMT and metastatic ca-
pacity in human breast cancer cells (Evdokimova et al., 2009), we
wondered whether YB-1 might also promote metastatic
behavior in sarcomas, which are already mesenchymal in origin.
RESULTS
YB-1 Is Elevated in High-Risk Sarcomas and Is
Associated with Poor Outcome
We assessed YBX1 mRNA expression in different human sar-
coma subtypes from publically available datasets (see Supple-
mental Experimental Procedures). YBX1 expression was higher
across all sarcoma types analyzed compared with non-
neoplastic tissues (Figure S1A). We then searched for sar-
coma-related gene expression datasets with links to outcome,
focusing on sarcoma subtypes with high metastatic rates (Ha-
Duong et al., 2015). TheGSE34620 dataset containing 117 cases
(Postel-Vinay et al., 2012) revealed significantly higher YBX1expression in metastatic compared with localized EWS (Fig-
ure 1A). Elevated YBX1 expression also correlates significantly
with higher mortality in EWS (Figure 1A), and high YBX1 expres-
sion correlates with poor overall survival in EWS (Figure 1B).
Elevated YBX1 expression at diagnosis is also associated with
reduced event-free survival in localized EWS (Figure S1B) and
overall survival in metastatic EWS (Figure 1C). High YBX1 levels
are associated with reduced overall (Figure 1D) and event-free
survival (Figure S1C) in OS and with reduced metastasis-free
survival in synovial sarcoma (Figure 1E). High YBX1 expression
showed a trend toward reduced survival in RMS, though not sig-
nificant because of small sample sizes (data not shown). Further
supporting a role in metastatic disease, elevated YBX1 expres-
sion also correlates with reduced overall and event-free or
metastasis-free survival in breast cancer, clear cell renal cell car-
cinoma, and cervical carcinoma (Figures S1D–S1H). Strong
cytoplasmic YB-1 staining by immunohistochemistry (IHC) was
observed in RMS compared with adjacent normal skeletal mus-
cle (Figure 1F) and in malignant OS cells compared with normal
osteoblasts (OBs) (Figure S1I). YB-1 IHC on 25 OS cases using
two independent YB-1 antibodies showed a correlation between
elevated YB-1 expression and higher grade disease (Table S1).
In EWS and OS cell lines, YB-1 levels were consistently elevated
compared with normal OBs and in RMS cell lines compared with
skeletal muscle (Figure 1G). Human fibroblasts andHEK293 cells
showed lower YB-1 expression compared with TC32 EWS cells
(Figure S1J). These data indicate that YB-1 expression is
elevated in high-risk sarcomas and is associated with poor
outcome.
YB-1 Increases Motility of Human Sarcoma Cells In Vitro
and In Vivo
To determine how YB-1 contributes to aggressiveness of sar-
comas, we first tested whether YB-1 increases cell migration
in vitro, a critical feature of the metastatic phenotype (Chaffer
and Weinberg, 2011). Given the high YB-1 expression in all sar-
coma cell lines tested, we chose a YB-1 siRNA knockdown (KD)
approach. Two or more independent siRNA sequences were
used, leading to consistent YB-1 KD (Figure S2A). YB-1 KD
significantly decreased MG63 OS cell migration in response to
10% fetal bovine serum (FBS), insulin, or insulin-like growth fac-
tor 1 (IGF1) (Figure 2A), and similarly reducedmigration ofMNNG
OS and TC32 EWS cells (Figures 2B and S2B). These and RH30
cells migrate more rapidly than corresponding YB-1 KD cells in
wound-healing assays (Figure S2C). YB-1 KD also significantly
reduced invasive capacity in vitro, shown for CHLA10 EWS cells
in Figure 2C, which was completely rescued by YB-1 re-expres-
sion using a siRNA-resistant expression plasmid. Moreover, in
Matrigel 3D matrices, control TC71 EWS cell clusters displayed
marked branching, whereas YB-1 KD clusters had rounded
morphology characteristic of non-invasive cells (Figure S2D).
Notably, YB-1 KD did not decrease proliferation rates of any of
the cell lines used in this study (data not shown).
To confirm effects on motility in vivo, we adapted a zebrafish
model, previously used to graft human leukemia cell lines into
48-hr embryos (Corkery et al., 2011), to xenotransplant TC32
cells into zebrafish embryos. TC32 cells were initially retained
in the yolk sac and then rapidly migrated to tails of embryos
within 120-hr post-injection (Figure 2D). Importantly, fixedCancer Cell 27, 682–697, May 11, 2015 ª2015 Elsevier Inc. 683
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Figure 1. Elevated YB-1 Expression Is Predictive of Poor Outcome in Sarcoma Patients
(A) Correlation between YBX1 mRNA level and metastatic disease or death in EWS patients using the GSE34620 database (n = 117) (Postel-Vinay et al., 2012).
Associations were determined using a Welch t test and the two-sided p values are displayed. Data are presented as box plots. The bars indicate the medians,
whereas the boxes represent the middle 50% of data points to graphically represent the interquartile range (IQR). The upper and lower whiskers represent the
largest and smallest observed values that are less than 1.5 box lengths from the ends of each box. Round circles represent outliers.
(B) Kaplan-Meier curves of overall survival for EWS patients in the GSE34620 database based on YBX1 expression, defined as low (25% of samples with lowest
expression), high (25% with highest expression), and medium (50% of samples with medium expression).
(C) Impact of YBX1 expression on overall survival (event = deceased) in EWS patients from the GSE34620 database with metastatic disease at diagnosis (n = 46).
(D) Kaplan-Meier curves showing the impact of YBX1 expression on overall survival for OS patients (Man et al., 2005).
(E) Kaplan-Meier metastasis free survival curve for synovial sarcoma patients (Lagarde et al., 2013) showing the impact of YBX1 expression on outcome.
(F) IHC staining for YB-1 expression in normal skeletal muscle and in RMS. Scale bars represent 100 mm.
(G) Western blot showing YB-1 expression in benign primary OBs and in the indicated OS and EWS cell lines (left) or in skeletal muscles compared with the
indicated RMS cell lines (right). GAPDH and Grb2 were used as loading controls.
See also Figure S1.TC32 cells and inert microspheres failed to migrate, confirming
that TC32 cell migration is an active rather than a passive pro-
cess (Figure 2E). Migration into embryo tails of TC32 cells with684 Cancer Cell 27, 682–697, May 11, 2015 ª2015 Elsevier Inc.YB-1 KD was significantly reduced compared with controls (Fig-
ures 2D–2F and S2E), while their proliferation was similar to con-
trols (Figure S2F). Similar results were obtained using a different
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Figure 2. YB-1 Increases Sarcoma Cell Motility In Vitro and In Vivo
(A) Cell migration of MG63 OS cells ± YB-1 KDmeasured as percent cells migrating to chambers without serum; serum starved (SS), 10% FBS, 100 nM insulin, or
100 ng/ml IGF1. Results of two independent experiments in triplicate are presented as means ± SD.
(B) Cell migration of MNNG OS (left) and TC32 EWS cells (right) ± YB-1 KD, measured as percentage of cells migrating to chambers without serum (SS) or 10%
FBS. The results of three independent experiments in triplicate are presented as means ± SD.
(C) In vitro invasion of CHLA10 EWS cells ± YB-1 KD and YB-1 KD cells with restored YB-1 expression (+YB-1). Results of two independent experiments in
triplicate are shown as means ± SD.
(D) TC32 EWS cells ± YB-1 shRNA KD were labeled with Cm-DiI and injected into 48-hr post-fertilization (hpf) casper zebrafish embryos. Bright-field (Bf) and
fluorescent (Fl) live lateral images of the head (anterior) and tail (posterior) of embryos at 24- and 120-hr post-injection (hpi) are shown (n = 15–20 embryos). Scale
bars represent 200 mm.
(legend continued on next page)
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shRNA (YB-1 KD #2; Figures S2G and S2H), providing strong ev-
idence that YB-1 increases cell motility of human sarcoma cells
in vivo.
YB-1 Increases Sarcoma Cell Invasion and Metastasis
In Vivo
To rigorously show that YB-1 facilitates aggressive behavior of
sarcoma cells in vivo, we next used the murine renal subcap-
sular implantation model for establishing human tumor xeno-
grafts (Bogden et al., 1979). This system is advantageous
due to extensive vascularization at the graft site and gives
rise to quantifiable metastases of diverse human tumor cell
lines (Cutz et al., 2006), including EWS cell lines (Mendoza-
Naranjo et al., 2013). CHLA10, TC71, and TC32 EWS cell
lines ± stable shRNA-mediated YB-1 KD were luciferase
(LUC) labeled and implanted under the renal capsules of
immunocompromised mice and assessed for local growth
and metastasis. Each cell line formed large tumors at primary
implantation sites after several weeks (shown for TC32 cells in
Figure S3A). There was no significant difference in gross sizes
of primary tumors between control and YB-1 KD tumors (Fig-
ure S3B). Histology revealed small round cell tumors charac-
teristic of EWS for each cell line (Figure 3A), confirmed by
strong membranous IHC staining for the CD99 EWS biomarker
(Figure S3C). YB-1 IHC confirmed reduced YB-1 levels in vivo
in KD tumors (Figure 3B), with two independent shRNAs tar-
geting YB-1 (Figure S3D). Supporting the above in vitro data,
there was no significant difference in proliferative rates be-
tween control and YB-1 KD tumors determined by Ki-67 IHC
(Figure S3E) or bromodeoxyuridine (BrdU) staining (data not
shown).
Notably, control CHLA10, TC71, and TC32 tumors were highly
infiltrative into adjacent normal kidney, whereas YB-1 KD tumors
were non-invasive and had ‘‘pushing’’ borders abutting but not
penetrating normal kidney (Figure 3A). Morphometric analysis
revealed highly significant differences in invasion into adjacent
normal kidney between control and KD tumors (Figure S3F).
We then used morphology (Figure 3C) and CD99 IHC (Fig-
ure S3G) to screen for lung metastases. YB-1 KD significantly
reduced the number of lung metastases per mouse for each
cell line (Figure 3D) and the total mice with lung metastases (Fig-
ures 3E and S3H), with complete elimination of metastases in the
CHLA10 group (Figure 3D). Similar results were obtained using
an independent shRNA targeting YB-1 (Figures 3F and S3D;
YB-1 KD #2). Restoring YB-1 expression rescued metastatic ca-
pacity in the CHLA10 YB-1 KD group (Figures 3F and 3G). YB-1
overexpression in CHLA10 control cells (Figures 3F and S3I) led
to slightly earlier metastatic spread (data not shown) but did not
increase overall metastases, as 100% of mice in both groups
eventually displayed lung metastases (Figure 3G). Of note, lung
metastases that did form in the YB-1 KD group displayed strong
YB-1 staining (Figure 3H), suggesting that in this group, metasta-
tic tumors formed either from clones that had escaped initial
YB-1 KD (Figure S3J, see arrows) or that re-expressed YB-1(E) Cell migration to tail regions after xenotransplantation into casper embryos. T
TC32 CTRL cells and Tetraspeck microspheres as controls; n = 160–180 embryo
(F) Migration of TC32 cells ± YB-1 KD to tail regions after xenotransplantation in
*p < 0.05, **p < 0.01, ***p < 0.001. hpi, hour post-injection. See also Figure S2.
686 Cancer Cell 27, 682–697, May 11, 2015 ª2015 Elsevier Inc.following initial silencing. Together, these findings provide
compelling evidence that YB-1 confers invasive and metastatic
capacity to sarcoma cells in vivo.
YB-1 Increases HIF1a Protein Levels in Sarcoma Cells
YB-1 induces metastasis of breast cancer cells through SNAI1
and TWIST translation (Evdokimova et al., 2009). However,
Snail1 was only very weakly expressed in the above sarcoma
cell lines, while Twist was not consistently reduced by YB-1
KD (data not shown). We therefore wondered whether other
EMT-associated transcription factors might be regulated by
YB-1 in sarcomas. Compared with control renal subcapsular xe-
nografts, tumors with YB-1 KD showed extensive hemorrhage
and necrosis (Figure 4A, asterisks; Figures S4A and S4B), typi-
cally found adjacent to areas of tumor hypoxia (Ho¨ckel and Vau-
pel, 2001). Indeed, there was extensive pimonidazole (pimo)
staining in both control and YB-1 KD tumors, indicating that
these lesions are hypoxic (Figures 4B and 4C), while adjacent
normal kidney was negative (Figures S4C and S4D). Since the
pro-angiogenic factor HIF1a is stabilized in viable hypoxic tumor
cells to regulate their survival under hypoxic stress and has well-
documented roles in cancer progression (Kaelin, 2011; Se-
menza, 2003), we wondered whether YB-1 might regulate
HIF1a expression. Indeed, HIF1a protein levels were markedly
reduced by YB-1 KD under 1% O2 using two independent
siRNAs in all sarcoma cell lines tested (Figure 4D; data not
shown). YB-1 KD blocked HIF1a accumulation even under nor-
moxia and after short-term growth at 1% O2, as shown for
MNNG cells in Figure 4E. YB-1 KD also reduced HIF1a expres-
sion under more stringent hypoxia at 0.2% O2 (Figure 4F).
Notably, YB-1 KD failed to reduce HIF2a accumulation under
hypoxia in MNNG and RH30 cells (Figure S4E) or in EWS cell
lines (data not shown).
To validate this in vitro, we used the multilayered cell culture
(MCC) system, in which an O2 gradient is generated across 3D
cultures of solid tumor cell lines (Minchinton et al., 1997). Using
pimo staining to highlight hypoxia (Figure S4F, left), YB-1 expres-
sion was largely limited to viable hypoxic regions adjacent to
central necrotic cores in TC32 MCC aggregates (Figure S4F,
right). YB-1 was similarly expressed in control MNNG aggre-
gates, which correlated with strong HIF1a expression, but
HIF1a was significantly reduced by YB-1 KD (Figure 4G), further
linking YB-1 to HIF1a expression. Residual HIF1a expression in
YB-1 KD aggregates may be attributable to YB-1-independent
HIF1a regulation or to residual clones escaping initial KD or
with shRNA silencing, as suggested in short-term MCC cultures
(Figure S4G). Finally, YB-1 overexpression using Myc-tagged
YB-1 in CHLA10 cells (see Figure 3F) moderately enhanced
in vitro HIF1a expression under both normoxia and hypoxia
compared with controls (Figure S4H).
To confirm that YB-1-induced HIF1a is biologically active, we
monitored activity of a hypoxia response element (HRE) reporter
linked to GFP in cells ± YB-1 KD with two independent siRNAs.
This revealed significantly higher HRE activity in controlC32 control (CTRL) versus YB-1 KD cells were compared at 120 hpi with fixed
s per group. Error bars indicate SD.
to casper embryos and mortality at the indicated time points.
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Figure 3. YB-1 KD Blocks Sarcoma Cell Metastasis In Vivo
(A) H&E-stained renal subcapsular primary tumor xenografts of CHLA10, TC71, and TC32 cell lines ± YB-1 shRNA KD. White arrows in control (CTRL) and YB-1
KD tumors show tumor-normal kidney interfaces. Scale bars represent 100 mm.
(B) IHC staining of YB-1 in primary tumor xenografts of the indicated EWS cell lines ± shRNA YB-1 KD. Scale bars represent 50 mm.
(C) H&E staining of metastatic lung lesions (arrows) in mice with renal subcapsular tumor xenografts of the indicated EWS cell lines ± shRNA YB-1 KD. Scale bars
represent 100 mm.
(D) Average number of lung metastases in mice bearing renal subcapsular tumor xenografts of CHLA10, TC71, and TC32 cell lines ± shRNA YB-1 KD compared
using a Wilcoxon two-sided rank sum test. Results are presented as mean ± SEM.
(E) Total number of mice bearing xenografts of CHLA10, TC71, and TC32 cell lines ± shRNA YB-1 KD that developed lung metastases, determined using a
Fisher’s exact test.
(legend continued on next page)
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compared with RH30 YB-1 KD cells under both normoxia and
hypoxia (Figure 4H). Next, we analyzed lysates from renal sub-
capsular xenografts of MNNG cells ± YB-1 KD for HIF1a expres-
sion and found markedly reduced HIF1a protein levels in KD
tumors in vivo (Figure S4I). Consistent with this, tumor cryosec-
tions showed markedly reduced staining for the HIF1a transcrip-
tional target carbonic anhydrase IX (CAIX) (Wykoff et al., 2000)
after YB-1 KD (Figure S4J). Therefore, YB-1 controls biologically
active HIF1a expression in sarcoma cell lines both in vitro and
in vivo. Finally, to assesswhether YB-1 regulates HIF1a in human
sarcomas, tissue microarrays (TMAs) from EWS (20 cases) and
RMS (41 cases) were immunostained for YB-1 and HIF1a.
YB-1 expression strongly correlated with HIF1a IHC in both
EWS and RMS (Figures S4K and S4L; Tables S2 and S3). These
data provide compelling evidence that YB-1 positively regulates
HIF1a protein expression in human sarcomas.
YB-1 Activates HIF1A Translation in Sarcoma Cells
We next determined how YB-1 regulates HIF1a expression
since YB-1 reportedly acts through both transcriptional and
translational mechanisms (Eliseeva et al., 2011). We first
compared total and polysome-bound (translationally active)
HIF1A mRNA levels in cells ± YB-1 KD by quantitative RT-
PCR (qRT-PCR). Total HIF1A mRNA levels in hypoxic RH30
and MNNG cells either increased or stayed the same after
YB-1 KD as in control cells (Figure 5A), arguing against a tran-
scriptional mechanism for YB-1 induction of HIF1a. In
contrast, YB-1 KD significantly reduced the proportion of
HIF1A transcripts in polysomal fractions (compare polysome
levels ± YB-1 KD in Figure 5A). Although HIF1A mRNA accu-
mulation in polysomes was increased under hypoxia, YB-1 KD
reduced this distribution under both normoxia and hypoxia
(Figure 5B). In contrast, neither HIF2A mRNA levels nor its pol-
ysomal distribution was consistently affected by YB-1 KD un-
der identical conditions (Figure S5A). This suggests that YB-1
enhances the proportion of HIF1A mRNAs undergoing active
translation. To support this, we next monitored levels of newly
synthesized HIF1a in control versus YB-1 KD cells, using
CLICK chemistry and L-azidohomoalanine (AHA) incorporation
as described (Somasekharan et al., 2012). Hypoxic MNNG
cells were pulsed with AHA, and AHA-labeled newly synthe-
sized proteins were biotinylated and affinity purified with strep-
tavidin. While control cells showed robust new synthesis of
HIF1a, this was almost completely blocked by YB-1 KD (Fig-
ure 5C). Together, these data indicate that YB-1 selectively in-
creases HIF1A mRNA translation under both normoxia and
hypoxia.
YB-1 Directly Binds to HIF1A mRNA to Control Its
Translation
One explanation for these data is that YB-1 directly binds to
and activates translation of HIF1A mRNAs, as described for(F) (Upper) IHC staining for YB-1 in primary xenografts of CHLA10 cell line ± YB-1 s
bars represent 50 mm. (Middle) H&E staining of metastatic lung lesions (arrows). S
lung tissues to highlight metastatic lesions. Scale bars represent 50 mm.
(G) Total numbers of mice from (F) that developed lung metastases compared us
(H) IHC staining of YB-1 in lung metastases of mice bearing xenografts of TC71
*p < 0.05, **p < 0.01. See also Figure S3.
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(RNP) immunoprecipitation (RIP) with anti-YB-1 antibodies
demonstrated that YB-1 associates with HIF1A transcripts in
MNNG cells (Figure 5D). YBX1 and CCND1 transcripts, known
to bind to YB-1 (Evdokimova et al., 2006b), were used as
positive controls and RPL32 as a negative control (Evdoki-
mova et al., 2006b). We then used a bicistronic reporter con-
taining the full-length HIF1A 50-UTR sequence cloned up-
stream of firefly LUC and Renilla LUC driven by the SV40
promoter (Bert et al., 2006) to assess whether the HIF1A
50-UTR impacts YB-1-driven mRNA translation efficiency in
cells. This revealed significantly higher LUC activity in
MNNG control versus YB-1 KD cells (Figure 5E), indicating
that in living cells, YB-1 facilitates translation of transcripts
containing the HIF1A 50-UTR. To directly test this, in vitro
translation efficiencies of a LUC reporter linked to the
50-UTR of either HIF1A (50-HIF1A-LUC) or HBB (beta-globin)
(50-HBB-LUC) were tested using a cell-free transcription/trans-
lation system (Bert et al., 2006). As shown in Figure 5F, re-
combinant YB-1 at up to 0.6 pmol increased the translation
efficiency of 50-HIF1A-LUC, while minimally affecting transla-
tion of 50- HBB -LUC. Above 0.6 pmol, YB-1 decreased trans-
lation from both 50-UTRs, as reported for the SNAI1 50-UTR
(Evdokimova et al., 2009) and consistent with the known
translational repressor function of YB-1 at high levels (Evdoki-
mova and Ovchinnikov, 1999).
Supporting a role for YB-1 in controlling HIF1A translation
efficiency, cross-species analysis reveals numerous conserved
GC-rich sequences in the HIF1A 50-UTR (Figure S5B), the
favored YB-1 binding sequence (Eliseeva et al., 2011), partic-
ularly in nucleotides 133–257 of the human 50-UTR. Vienna
RNA secondary structure prediction tools (http://rna.tbi.
univie.ac.at/cgi-bin/RNAfold.cgi) predict that the HIF1A 50-
UTR forms highly stable stem loop structures (Figure S5C)
and thus may be susceptible to YB-1 helicase-mediated
melting of its secondary structure, as described for the
SNAI1 50-UTR (Evdokimova et al., 2009). We therefore
compared activity of the above WT HIF1A 50-UTR-LUC re-
porter to that of deletion mutants lacking either nucleotides
1–130 (D1–130) or 131–253 (D131–254) of the HIF1A 50-UTR.
There was a marked reduction in YB-1-induced LUC activity
for the D131–254 mutant compared with the WT construct,
which was less evident with the D1–130 mutant (Figure 5G);
YB-1 KD reduced activity of all three constructs. The same re-
porter substituted with WT HIF2A 50-UTR was not activated by
YB-1 (Figure 5G), consistent with YB-1 not affecting polysomal
distribution of HIF2A mRNAs (Figure S5A). Finally, electropho-
retic mobility shift assays (EMSAs) demonstrated direct
binding of YB-1 to WT HIF1A 50-UTR probe in a concentra-
tion-dependent manner (Figure 5H), which was completely in-
hibited with unlabeled probe. While both unlabeled D1–130
and D131–253 mutant probes reduced YB-1 binding to thehRNA KD #2, YB-1 re-expression (+YB-1), or YB-1 overexpression (O/E). Scale
cale bars represent 100 mm. (Lower) IHC staining of the EWS marker CD99 in
ing a Fisher’s exact test.
and TC32 cell lines ± shRNA YB-1 KD. Scale bars represent 100 mm.
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Figure 4. YB-1 Is Associated with Increased HIF1a Protein Expression in Sarcoma Cells
(A) H&E-stained renal subcapsular tumor xenografts of TC71 and TC32 EWS cells ± shRNA YB-1 KD. Asterisks show areas of necrosis. Scale bars represent
100 mm.
(B) Assessment of hypoxia in MNNG tumor xenografts using pimonidazole hydrochloride. Pimonidazole was injected 90 min prior to sacrifice and stained in
cryosections using pimonidazole antibodies to highlight hypoxic areas (green). Scale bars represent 150 mm.
(C) Pimonidazole staining within tumors of (B) were quantitated as group averages ± SEM for the sample mean, whereby whole tissue sections were analyzed for
each tumor (n = 8 per group).
(D) Western blot of HIF1a expression in TC32 and CHLA10 cells ± siRNA YB-1 KD grown under normoxia or hypoxia (1%O2) for 4 hr. Grb2 was used as a loading
control.
(E) Western blot of HIF1a and YB-1 expression in MNNG cells ± YB-1 KD grown under hypoxia for the indicated time points. Grb2 was used as a loading control.
(legend continued on next page)
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WT 50-UTR, D131–253 was less efficient, particularly at higher
concentrations (Figure 5H; compare supershifted bands in
lanes 7 versus 9). While not definitive, this further supports a
role for nucleotides 131–254 (containing the majority of CG
islands) in YB-1 binding to the HIF1A 50-UTR. Together, these
data strongly support a role for YB-1 in translational activation
of HIF1A, likely through direct effects of YB-1 on HIF1A mRNA
translational efficiency.
YB-1 Regulates HIF1a Expression Independently of VHL
To assess potential effects of YB-1 on HIF1a protein stability,
we treated CHLA10 cells with cycloheximide to block transla-
tion and measured HIF1a degradation rates. As shown in Fig-
ures 6A and 6B, degradation rates were unchanged between
control and YB-1 KD cells, arguing against YB-1 regulating
HIF1a protein stability. Moreover, the MG132 proteasome in-
hibitor failed to completely rescue HIF1a protein levels under
normoxia in CHLA10 cells with YB-1 KD (Figure S6A), and
YB-1 KD did not affect components of the Elongin B/C-
CUL2-VHL (ECV) E3 ligase complex (Figure S6B), which targets
HIF1a for proteasomal degradation (Ivan et al., 2001; Jaakkola
et al., 2001). To rigorously rule this out, we tested whether YB-1
could regulate HIF1a protein expression in RCC4 renal carci-
noma cells. These cells stabilize HIF1a due to inactivation of
the ECV E3 ligase through loss-of-function mutations of VHL
(Maxwell et al., 1999). YB-1 KD in RCC4 cells led to marked
loss of HIF1a protein expression under both normoxia and hyp-
oxia, as well as in RCC4 cells with reconstituted expression of
functional VHL (Figure 6C). This provides compelling evidence
that YB-1 regulation of HIF1a protein levels in tumor cells is in-
dependent of the ECV HIF1a E3 ligase. To test whether YB-1
regulates HIF1a in other epithelial tumors, we performed YB-
1 KD with two independent siRNAs (Figure S6C) under both
normoxia and hypoxia in diverse epithelial tumor cell lines.
YB-1 KD markedly reduced HIF1a expression under hypoxia
in prostate carcinoma (PC3 and LNCap) but not benign pros-
tate epithelial cells (BPH1; Figure S6D), and in melanoma
(MeWo), lung carcinoma (H1299), and breast carcinoma cells
(MDA-MB-231, MCF7, and T47D; Figure S6E). While YB-1 is
expressed in hypoxic non-tumorigenic human embryonic kid-
ney HEK293 cells (Figure S6F) and normal fibroblasts (data
not shown), this was not linked to increased HIF1a protein in-
duction in these cells, which along with the above BPH1 re-
sults, point to a specific role of YB-1 in regulating HIF1a in
transformed cells. Finally, we overexpressed Myc-tagged
YB-1 in HeLa cervical carcinoma cells, which moderately but
significantly enhanced HIF1a expression under hypoxia
compared with vector alone cells (Figure S6G; compare bars
in the right). Together, these data strongly support a role for
YB-1 in translational activation of HIF1A independent of the
ECV E3 ligase and indicate that YB-1 regulation of HIF1a pro-(F) Effects of independent siRNAs targeting YB-1 (#1 and #2) onHIF1a protein leve
loading control.
(G) 3D tissue discs of MNNG cells were grown on collagen-coated tissue culture in
tissue discs were examined by IHC for YB-1, HIF1a, and pimonidazole (scale ba
(H) HRE-GFP activity in RH30 RMS cells ± siRNA YB-1 KD under normoxia and 1
50 mm) and quantified (mean of five fields ± SD).
*p < 0.05, ***p < 0.001. See also Figure S4.
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to sarcomas.
HIF1a Is a Critical Effector of YB-1-Mediated Sarcoma
Invasion and Metastasis
We next assessed whether HIF1a is important for YB-1-
induced invasion and metastasis of sarcoma cells. HIF1a KD
with two independent siRNAs in YB-1-competent MNNG cells
(Figure S7A) significantly inhibited in vitro invasion under both
normoxia and hypoxia and to a similar extent as YB-1 KD (Fig-
ure 7A). We then expressed either WT HIF1a or the HIF1a
P402A/P564A Pro-to-Ala double mutant (resistant to HIF1a
degradation) (Masson et al., 2001) in MNNG YB-1 KD cells (Fig-
ure S7B). Expression of either isoform almost completely
rescued invasive capacity of YB-1 KD cells under both nor-
moxia and hypoxia (Figure 7B), highlighting HIF1a as a critical
in vitro effector of YB-1-mediated sarcoma cell invasion. To
assess this in vivo, we ectopically expressed HIF1a in
CHLA10 and MNNG cells with stable YB-1 KD and monitored
morphology of renal subcapsular xenograft tumors. YB-1 KD
tumors again showed extensive hemorrhage and necrosis,
which was almost completely rescued by HIF1a re-expression
(compare Figures 7Ca–f and see Figure S7C). Expression levels
of YB-1 and HIF1a were determined by IHC as above (Figures
7Cg–r). We then determined whether HIF1a re-expression
could rescue pulmonary dissemination of YB-1 KD cells in
this model. While YB-1 KD again dramatically reduced metasta-
tic capacity, this property was significantly increased in the
same cells re-expressing HIF1a (Figures 7Cs–aa and 7D). By
comparison, YB-1 overexpression in CHLA10 cells (see Figures
S3I and S4H) did not alter their metastatic capacity (see Fig-
ure 3G), likely because this led to only slight increases in
HIF1a in vivo (Figure S7D). Finally, to confirm HIF1a function-
ality in this system, we examined expression of CAIX, a well-es-
tablished HIF1a target (Wykoff et al., 2000). CAIX expression
was significantly reduced in MNNG tumors with YB-1 KD, but
expression was rescued by HIF1a re-expression in the same
cells (Figure 8A). Moreover, since HIF1a is a major driver of
angiogenesis (Semenza, 2008) and because YB-1 KD increases
hemorrhage and necrosis in xenografts (Figure 4A), we also as-
sessed tumor microvessel density in EWS cell line xenografts ±
YB-1 KD, using IHC for the endothelial marker, CD31. This re-
vealed highly significant decreases in CD31 staining and
mean microvessel density in tumors derived from YB-1 KD
compared to control cell lines (Figure 8B). This was confirmed
using other blood vessel markers, namely endoglin (Figure S8A)
and CD34 (Figure S8B). Ectopic HIF1a expression in YB-1 KD
tumor xenografts rescued blood vessel formation (Figure 8C).
Together, these data show that YB-1 induces functionally
active HIF1a in vivo and highlight HIF1a as a major effector of
YB-1-mediated metastatic capacity of sarcoma cells.ls in the indicated cell lines incubated overnight at 0.2%O2. Grb2was used as a
serts for 16 hr prior to their transfer to stirred growth vessels. Cryosections from
rs represents 150 mm), and staining intensities were quantified (mean ± SD).
% O2 (24 hr) was detected by fluorescence microscopy (scale bars represent
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Figure 5. YB-1 Translationally Activates HIF1A Transcripts in Sarcoma Cells
(A) HIF1AmRNA expression in RH30 (left) and MNNG cells (right) ± siRNA YB-1 KD grown under normoxia (4 hr), as measured by qRT-PCR of total or polysomal
fractionated RNA. Values were normalized against GAPDH from two experiments performed in triplicate and are presented as means ± SD.
(B) Total and polysomal YBX1 and HIF1AmRNA levels in MG63 cells ± siRNA YB-1 KD grown under normoxia or 1%O2 (4 hr), as measured by qRT-PCR. Values
were normalized against GAPDH from two runs performed in triplicate and are presented as means ± SD.
(C) Affinity purification of biotinylated L-azidohomoalanine (AHA)-labeled acutely synthesized proteins from cell lysates ± YB-1 KD. Purified HIF1a and YB-1
proteins were then immunoblotted as indicated. Grb2 was used as a loading control.
(D) Fold change of HIF1AmRNA bound to YB-1 as measured by qRT-PCR following YB-1 immunoprecipitation. Controls include known YB-1 bound transcripts,
YBX1 and CCND1, and a known non-YB-1 binding transcript, RPL32. Values are normalized against XIAP from two runs in triplicate and presented as
means ± SD. Normal rabbit serum (NRS) was used as an immunoprecipitation control.
(legend continued on next page)
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DISCUSSION
Modern multi-agent chemotherapy and radiation regimens have
markedly improved outcomes for localized forms of high-risk
sarcomas such as EWS, OS, and RMS. However, the prognosis
for patients with metastatic disease remains dismal, with almost
no improvements in outcome for the past 20 years. While gene
fusions have been identified in many sarcomas, these are pre-
sent in both localized and widespread disease and thus do not
account for metastatic behavior. YB-1 protein levels are mark-
edly elevated in EWS, RMS, and OS, and expression correlates
with poor outcome and metastatic disease. Moreover, YB-1 fa-
cilitates sarcoma cell invasive and metastatic capacity through
direct binding to and translational activation of HIF1A mRNA,
highlighting YB-1 as an invasion and metastasis factor in high-
risk sarcomas through translational upregulation of HIF1a.
Hypoxia plays a dominant role in tumor invasion and metas-
tasis (Finger and Giaccia, 2010). Moreover, both YB-1 and
HIF1a promote metastatic dissemination in diverse cancers (Ev-
dokimova et al., 2009; Gluz et al., 2009; Lee et al., 2009), poten-
tially through common mediators such as Twist (Evdokimova
et al., 2009; Yang et al., 2008), including sarcomas (Eisinger-Ma-
thason et al., 2013). However, a link between YB-1 and HIF1a
has not been established. Prior studies of HIF1a regulation under
hypoxia have largely focused on transcriptional activation or pro-
tein stabilization. Stress-induced translation of HIF1a remains
poorly understood, even though it may play a critical regulatory
role under hypoxia (Hui et al., 2006). YB-1 is a prominent RNA-
binding protein and a well-established regulator of mRNA trans-
lation (Eliseeva et al., 2011). We show that YB-1 directly binds to
the HIF1A 50-UTR, that HIF1A transcripts are enriched in poly-
somes of control versus YB-1 KD sarcoma cells, and that YB-1
dramatically enhances acute synthesis of HIF1a. Since the
HIF1A 50-UTR contains complex stem loop structures similar to
those of SNAI1, it is likely that by binding to 50-UTR secondary
structures, YB-1 unwinds these structures to increase transla-
tional efficiency, as we reported for YB-1 induction of SNAI1
and TWIST translation (Evdokimova et al., 2009).
Our study suggests that YB-1-mediated HIF1AmRNA transla-
tion occurs under both normoxia and hypoxia. Indeed, YB-1 is
still required for HIF1a protein expression even when HIF1a is
stabilized under normoxia in RCC4 cells, which lack VHL
(Maxwell et al., 1999). It was previously reported that translation
of HIF1A mRNA is enhanced under hypoxia in a 4EBP1/eIF4G-
dependent and cap-independent manner, while translation of(E) Translational efficiency of a bicistronic mRNA reporter construct containing th
simian virus 40 (SV40) promoter, in MNNG cells ± YB-1 KD under normoxia. Resu
in triplicate.
(F) In vitro cell-free translation assay using reporter constructs withHIF1A orHBB 5
amounts of recombinant YB-1 protein and assessed for LUC activity. Results ar
triplicate.
(G) A bicistronic mRNA reporter construct as in (E) containing the full-length HIF1
was used to assess translation efficiency in CHLA10 cells ± YB-1 KD under 1%
periments performed in triplicate.
(H) Electrophoretic mobility gel shift assay (EMSA) to detect binding of recombina
probe (Bio-UTP-HIF1a 50-UTR) and unlabeled full-lengthHIF1A 50-UTR (lanes 4 an
6 and 7) or 1–130 (D1–130; lanes 8 and 9) were incubated with recombinant GST-Y
shows supershifted Bio-UTP-RNA probe/YB-1 complexes. (Right) Longer expos
*p < 0.05; **p < 0.01, ***p < 0.001. See also Figure S5.
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et al., 2007). YB-1-mediated HIF1A translation may be distinct
from this process, given its activity under both normoxia and
hypoxia, and may represent a more general mechanism that tu-
mor cells can use to maintain HIF1a levels. HIF1a accumulation
would then be further amplified under hypoxia through inactiva-
tion of prolyl hydroxylase activity (Kaelin, 2011).
YB-1 did not influenceHIF2A translation or protein levels, even
though the HIF2A 50-UTR is also predicted to contain complex
secondary structures. Using the above Vienna prediction tool,
the calculated melting temperature for the HIF1A 50-UTR is
115.59 kcal/mol compared with 198.53 kcal/mol for the
HIF2A 50-UTR. Therefore, one explanation for this discrepancy
is that YB-1 is unable to melt the more stable HIF2A 50-UTR
and thus fails to promote HIF2A translation. Alternatively,
sequence differences may preclude binding of YB-1 to the
HIF2A 50-UTR, and additional studies are required to address
this question. Separate translational regulation of HIF1A and
HIF2A might be advantageous to cells for maintaining indepen-
dent control of HIF1A and HIF2A target genes.
Independent of effects on proliferation, YB-1 KD dramatically
reduced invasion and metastatic capacity of sarcoma cells im-
planted under the renal capsules of immunocompromised
mice, which was rescued by re-expression of HIF1a. However,
our studies do not rule out roles for other YB-1 translational tar-
gets. For example, YB-1 promotes translation of TWIST (Evdoki-
mova et al., 2009). Moreover, TWIST is transcriptionally acti-
vated by HIF1a in epithelial tumor cells, leading to increased
metastasis (Yang et al., 2008). Expression of TWIST is reported
in human sarcomas, but in association with an alternative mech-
anism of p53 inactivation in p53 WT leiomyosarcomas and lipo-
sarcomas, rather than with increased invasiveness (Piccinin
et al., 2012). Moreover, we failed to detect a consistent link be-
tween YB-1 and TWIST expression in EWS, OS, and RMS.
YB-1 also translationally regulates TGFB1 mRNA (Fraser et al.,
2008), known to mediate EMT and cancer metastasis (Taylor
et al., 2013). Further studies are required to explore how these
and other YB-1 translational targets might contribute to YB-1-
mediated sarcoma metastasis.
In summary, these studies highlight a mechanism for HIF1a
regulation in high-risk sarcomas through YB-1-mediated trans-
lation, which contributes to metastasis in these diseases. YB-1
may therefore represent an exciting target for therapeutic
intervention in sarcomas. Alternatively, targeting HIF1a itself
or its downstream effectors may offer more tractable clinicale full-length HIF1A 50-UTR upstream of firefly LUC, and Renilla LUC driven by
lts are displayed as means ± SD from two independent experiments performed
0-UTRs linked to the SP6 RNA polymerase promoter incubated with increasing
e displayed as means ± SD from two independent experiments performed in
A 50-UTR, its mutants M1 (D131–254 nt), M2 (D1–130 nt), or the HIF2A 50-UTR
O2 for 4 hr. Results are displayed as means ± SD from two independent ex-
nt YB-1 to the HIF1A 50-UTR. (Left) Biotin end-tagged full-length HIF1A 50-UTR
d 5) or 50-UTR deletion mutants lacking nucleotides 131–254 (D131–254; lanes
B-1. Double arrows show free probe (Bio-UTP-RNA) while the single arrowhead
ure of the same figure.
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Figure 6. YB-1 Regulates HIF1a Expression Independently of VHL
(A) Immunoblots showing HIF1a protein decay in CHLA10 cells ± YB-1 KD at
the indicated time points after cyclohexamide (CHX) addition under 1% O2.
Grb2 was used a loading control.
(B) Graphical representation of HIF1a protein levels from (A) based on densi-
tometry. Half-lives are shown under the curves, representing results of two
independent experiments ± SD.
(C) Western blots of HIF1a, YB-1, and VHL expression in RCC4 (VHL-deficient)
and RCC4-VHL (VHL re-expressed) cells ± YB-1 KD with two independent
siRNAs and grown under 21% or 1% O2 for 4 hr as indicated. Grb2 was used
as a loading control.
See also Figure S6.strategies. Notably, effects of YB-1 on HIF1a translation were
not apparent in non-transformed cells, although the basis for
this discrepancy remains unknown. Our observation that
YB-1 also regulates HIF1a protein levels in diverse epithelial
tumor cell lines in an ECV E3 ligase-independent manner sug-
gests that the proposed mechanism may be more broadly
applicable in cancer biology. The xenograft systems we
describe should provide robust preclinical models to evaluate
HIF1a pathway-targeting agents alone or in combination with
other therapies to inhibit the spread of cancer cells mediated
by YB-1.
EXPERIMENTAL PROCEDURES
Cell Lines
OB3 and OB5 primary OBs were developed as previously described (El Nag-
gar et al., 2012). Primary human fibroblasts were kindly provided by Dr. Con-
nie Eaves (University of British Columbia). RCC4 vector alone and RCC4-VHL
cells were a kind gift of Dr. Michael Ohh (University of Toronto). The CHLA10
EWS cell line was kindly provided by Dr. Patrick Reynolds (Texas Tech Univer-
sity). TC71, TC32 EWS cell lines, and RH18 and RH30 RMS cell lines were gifts
from Dr. Timothy Triche (Children’s Hospital Los Angeles). Other cell lines
were obtained from the American Type Culture Collection (ATCC). Culture
conditions for each cell line are described in Supplemental Experimental
Procedures.
Animal Studies
Murine renal subcapsular implantation studies were approved by the Uni-
versity of British Columbia Animal Care Committee, while zebrafish experi-
ments were approved by the Dalhousie University Animal Care Committee.
Detailed procedures are described in the Supplemental Experimental
Procedures.
Ethics Approvals
IHC studies on human tissue samples were approved by the University of
British Columbia Research Ethics Board (UBC REB Number H02-61375).
MCC System for 3D Cell Cultures
3D tissue discs were grown by seeding 1- to 4-ml cells (500,000 cells/ml) into
collagen-coated tissue culture inserts (CM 12mm, pore size 0.4 mm;Millipore).
Seeded inserts were incubated for 16 hr and transferred to stirred growth ves-
sels (Minchinton et al., 1997). Tissues were then grown for 5 days under 5%
O2, 5% CO2 at 37
C. After 5 days, 100 mM BrdU (Sigma) and 50 mM pimoni-
dazole (Hypoxyprobe) were added to label proliferation and hypoxia,
respectively.
Western Blotting, Reagent, Immunofluorescence, and Antibodies
Western blotting and immunofluorescence were conducted using standard
procedures. Human skeletal muscle tissue lysate was purchased from Abcam
(Catalog number ab2933). Antibodies used are summarized in the Supple-
mental Experimental Procedures.
RNA Isolation and qRT-PCR
Total RNA was extracted as previously described (Peppel and Baglioni, 1990).
Real-time quantitative PCR was performed using an ABI ThermoCycler (ABI
Prism 7700 SDS). Human primers used are described in Supplemental Exper-
imental Procedures.
HIF1a Overexpression
Sarcoma cell lines ± YB-1 KDwere transfected with 500 ng of vector encoding
WT or a degradation-resistant HIF1a-P402A/P564A proline to alanine mutant,
kind gifts of Dr. Thilo Hagen (University of Singapore) or empty vector using
siLentFect. At 1-day post-transfection, cells were incubated under normoxia
(21% O2) or hypoxia (1% O2) for 24 hr. Cells were then lysed and analyzed
for HIF1a expression by western blotting using Cayman HIF1a rabbit poly-
clonal antibody.Cancer Cell 27, 682–697, May 11, 2015 ª2015 Elsevier Inc. 693
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Figure 7. HIF1a Mediates the Invasive Phenotype of Sarcoma Cells
(A) Effects of YB-1 or HIF1a siRNAs KD on invasive capacity of MNNG cells under normoxia and 1%O2 (8 hr) as assessed using in vitro invasion assays. Results
are displayed as means ± SD from two independent experiments performed in triplicate.
(B) Effects of ectopic expression of WT or P402A/P564Amutant HIF1a on invasive capacity of MNNG cells with siRNA YB-1 KD under normoxia and 1%O2 (8 hr),
as assessed by in vitro invasion assays. Results are displayed as means ± SD from two independent experiments in triplicate.
(C) Primary tumors and lungs from mice bearing renal subcapsular tumor xenografts of CHLA10 and MNNG cell lines ± shRNA YB-1 KD and with or without
ectopic WT HIF1a expression. (a–f) H&E staining of primary xenografts of the indicated cell lines. (g–l) IHC of YB-1 in primary xenografts. (m–r) IHC of HIF1a in
primary xenografts. (s–x) H&E staining of lung metastases (arrows) in the indicated mouse groups. (y–aa) IHC of the CD99 EWS marker in lungs of mice bearing
CHLA10 tumor xenografts. Scale bars represent 100 mm.
(D) Total number ofmice bearing CHLA10 orMNNG xenografts ± YB-1 KD that developed lungmetastases comparedwithmicewith xenografts of the same YB-1
KD cell lines but ectopically expressing WT HIF1a, as determined using a Fisher’s exact test.
*p < 0.05, **p < 0.005, ***p < 0.0005. See also Figure S7.
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Figure 8. YB-1 Mediates Microvessel Density in Sarcoma Xenografts
(A) (Left) IHC of CAIX in tumor xenografts of CHLA10 cells ± shRNA YB-1 KD and cells with YB-1 KD plus ectopic WT HIF1a expression. Asterisks show areas of
necrosis. Scale bars represents 25 mm. (Right) Quantitation of CAIX-positive cells.
(B) (Left) Tumor microvessel density in primary xenografts of TC71, TC32, and CHLA10 cell lines ± shRNA YB-1 KD, as detected by CD31 IHC. Scale bars
represent 50 mm. (Right) Quantitation of microvessel density.
(C) (Left) IHC of CD31 expression in tumor xenografts of CHLA10 cells ± shRNA YB-1 KD versus cells with YB-1 KD plus ectopicWTHIF1a expression. Scale bars
represent 50 mm. (Right) Quantification of tumor microvessel density in tumor xenografts.
Statistical analysis was conducted using a two-tailed student’s t test, and results are presented as mean ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S8.
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SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and three tables and can be found with this article online at
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